Research of the influence of the mass fraction of ciminal in suppositories on the level of their antimicrobial activity
DOI:
https://doi.org/10.14739/2409-2932.2026.2.356892Keywords:
drugs, antimicrobial activity, excipients, active pharmaceutical ingredientsAbstract
The modern concept of treatment of infectious urogenital lesions is based on purposeful etiotropic and pathogenetically justified prescription of effective drugs. At the same time, the correct choice of medical tactics and appropriate pharmacotherapeutic agents, considering the specific features of the pathology, becomes of paramount importance. For the successful implementation of this direction, the use of active pharmaceutical ingredients is promising, which, along with a wide range of antibacterial and antimycotic effects and a minimum level of toxicity, does not cause the appearance of resistant strains of sexually transmitted pathogens. The creation of effective, complementary and accessible for practical medicine vaginal dosage forms based on innovative compounds containing halide substituents will increase the efficiency of venereal care and improve the reproductive health of the population of Ukraine.
The aim of this work is to determine the optimal amount of ciminal in vaginal suppository compositions.
Materials and methods. The effect of the mass fraction of ciminal in vaginal suppositories was evaluated on model polyethylene oxide carrier compositions with the addition of 0.05 ml of dimexide, which, according to the literature, increases its solubility and degree of antimicrobial activity. The amount of ciminal in the studied vaginal dosage forms was 0.01–0.15 g, taking into account the average suppository weight of 3 g. The study was conducted using a mathematical plan of one-factor analysis of variance with repeated observations. As an optimization parameter, the level of specific activity of experimental suppository masses was used, which was evaluated by diffusion into agar against gram-negative Pseudomonas aeruginosa and Candida albicans fungi, the lesion of which urethral pathways is a serious clinical problem, considering their prevalence and high resistance to pharmacotherapy.
Results. It was found that the studied vaginal suppositories containing different amounts of ciminal exhibit a sufficiently high level of antibacterial and antimycotic activity, the level of which increases with increasing dose of the active substance.
Conclusions. Studies of the antimicrobial activity of suppository compositions with ciminal prove that their effectiveness is statistically significantly influenced by the mass fraction of the active pharmaceutical ingredient. It was found that the optimal level of antimicrobial activity of the soft vaginal dosage form provides a mass fraction of ciminal in an amount of 0.15 g, taking into account the average mass of suppositories of 3 g.
References
- McArthur M, Patel M. A pictorial review of genitourinary infections and inflammations. Clin Imaging. 2023;104:110013. doi: https://doi.org/10.1016/j.clinimag.2023.110013
| 
| 
- Van Gerwen OT, Muzny CA, Marrazzo JM. Sexually transmitted infections and female reproductive health. Nat Microbiol. 2022;7(8):1116-26. doi: https://doi.org/10.1038/s41564-022-01177-x
| | - Tuddenham S, Hamill MM, Ghanem KG. Diagnosis and Treatment of Sexually Transmitted Infections: A Review. JAMA. 2022;327(2):161-72. doi: https://doi.org/10.1001/jama.2021.23487
| | - Boddu S, Karthikeyan, Mandava K. A comprehensive review of urinary tract infections: pathophysiology, antibiotic resistance, and therapeutic strategies, with emphasis on herbal alternatives. Reviews and Research in Medical Microbiology. 2026;37(2):65-78. doi: https://doi.org/10.1097/mrm.0000000000000400
| - Loubet P, Ranfaing J, Dinh A, Dunyach-Remy C, Bernard L, Bruyère F, et al. Alternative Therapeutic Options to Antibiotics for the Treatment of Urinary Tract Infections. Front Microbiol. 2020;11:1509. doi: https://doi.org/10.3389/fmicb.2020.01509
| | - Simoni A, Schwartz L, Junquera GY, Ching CB, Spencer JD. Current and emerging strategies to curb antibiotic-resistant urinary tract infections. Nat Rev Urol. 2024;21(12):707-22. doi: https://doi.org/10.1038/s41585-024-00877-9
| | - Zawadzka M, Laudy AE. Antiseptics: Their characteristics, application and challenges in the 21St century resulting from the spread of antimicrobial resistance (AMR). Advancements of Microbiology. 2025;64(3):112-40. doi: https://doi.org/10.2478/am-2025-0010
- Mahant S, Sharma AK, Gandhi H, Wadhwa R, Dua K, Kapoor DN. Emerging Trends and Potential Prospects in Vaginal Drug Delivery. Curr Drug Deliv. 2023;20(6):730-51. doi: https://doi.org/10.2174/1567201819666220413131243
| | - Kravchenko VG, Kravchenko AV. [Analysis of locally irritating action of the Cidipol drug in the form of ear drops]. Dermatovenerolohiia. Kosmetolohiia. Seksopatolohiia. 2018;(1-4):78-80. Ukrainian. Available from: http://repo.dma.dp.ua/id/eprint/4313
- Loban G, Kravchenko V, Ananyeva M, Kravchenko A, Faustova M. Antibacterial and anti-fungal effect of antiseptic preparation “Cidipol”. Actual Problems of the Modern Medicine. 2020;20(2):145-9. Ukrainian. doi: https://doi.org/10.31718/2077-1096.20.2.145
- Kumar A, Kumar S. Intra vaginal drug delivery system (novel drug delivery system). Int j res appl sci biotechnol. 2020;7(6):234-41. doi: https://doi.org/10.31033/ijrasb.7.6.33
- Kravchenko V, Kravchenko A, Yemchenko Y, Dudchenko M. [Topical antibacterial agents under conditions of antibiotic resistance of the microbiome (an analytical review of the problem and prospects for the development of new topical antibacterial (antiseptic) agents)]. Problemy ekolohii i medytsyny. 2022;26(3-4):44-50. Ukrainian. doi: https://doi.org/10.31718/mep.2022.26.3-4.07
- Hroshovyi TA, Martseniuk VP, Kucherenko LI, Vronska LV, Hureieva SM. Matematychne planuvannia eksperymentu pry provedenni naukovykh doslidzhen v farmatsii. Ternopil, Ukraine: TDMU, 2008. Ukrainian.
- Pashayan MM, Hovhannisyan HG. Development of bifunctional vaginal suppositories by joint use terconazole and probiotic for treatment and prophylaxis of vulvovaginal candidiasis. Drug Dev Ind Pharm. 2021;47(9):1424-31. doi: https://doi.org/10.1080/03639045.2021.2001485
| | - Reynolds D, Kollef M. The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update. Drugs. 2021;81(18):2117-31. doi: https://doi.org/10.1007/s40265-021-01635-6
| | - Faustino M, Ferreira C, Pereira AM, Carvalho AP. Candida albicans: the current status regarding vaginal infections. Appl Microbiol Biotechnol. 2025;109(1):91. doi: https://doi.org/10.1007/s00253-025-13478-2
| |
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 M. Yu. Zeleniuk, N. L. Kolycheva
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
